Atrial Fibrillation

An analysis of U.K. Biobank data found that lipoprotein(a) may impact atrial fibrillation risk. Researchers said the link was independent of lipoprotein(a)’s effect on atherosclerotic CVD. It was the top story in cardiology last week.

Lipoprotein(a) may have a causal role in incident atrial fibrillation risk, independent of its effect on atherosclerotic CVD, according to an analysis of U.K. Biobank data.

Researchers estimated that the lifetime benefit of smoking cessation on major cardiovascular events was similar to the use of several pharmaceutical treatments. It was the top story in cardiology last week.

The FDA has cleared Fitbit’s photoplethysmography-based algorithm to detect atrial fibrillation in wearers of its devices, the company announced.

Healio and Cardiology Today have compiled a list of the top read news in cardiology of March 2022.

New-onset CV complications after ischemic stroke predicts worse 5-year prognosis for major adverse CV events, including death, according to new research published in Stroke.

Firefighters who responded to a higher number of fires per year had a significantly greater risk for developing atrial fibrillation than those who responded to fewer fires, according to a recent study.

In patients with ACS, the PCSK9 inhibitor alirocumab did not impact the development of atrial fibrillation compared with placebo, according to new data from the ODYSSEY Outcomes trial.

Catheter ablation for atrial fibrillation in patients with mechanical valve prostheses conferred similar risk for periprocedural complications and mortality as in patients without prosthetic valves, data show.

Dronedarone for atrial fibrillation may lower risk for all-cause death and CV hospitalization regardless of HF status or left ventricular ejection fraction, according to research published in the European Journal of Heart Failure.